Abstract
Monoclonal antibodies have undergone a radical evolutionary journey over the last 25 years, with advances in molecular biology, process development and drug formulation underpinning their rise to becoming one of the most efficacious and economically important class of drug today. The success of antibodies for the treatment of rheumatological conditions, such as rheumatoid arthritis in particular, has driven the biopharmaceutical industry to optimize all aspects of therapeutic antibody discovery and development, in order to provide further benefits for patients over and above marketed treatments, via increased clinical efficacy and patient convenience. Recent advances in many of the key aspects of antibody design that are driving this evolution, such as affinity optimization, effector function modulation, pharmacokinetic engineering, as well as developments in subcutaneous drug delivery, are reviewed here.
Keywords: Antibody, rheumatology, affinity maturation, subcutaneous delivery, effector function.
Current Pharmaceutical Design
Title:Rheumatology: A Force for Change in Monoclonal Antibodies
Volume: 21 Issue: 17
Author(s): David C. Lowe and Tristan J. Vaughan
Affiliation:
Keywords: Antibody, rheumatology, affinity maturation, subcutaneous delivery, effector function.
Abstract: Monoclonal antibodies have undergone a radical evolutionary journey over the last 25 years, with advances in molecular biology, process development and drug formulation underpinning their rise to becoming one of the most efficacious and economically important class of drug today. The success of antibodies for the treatment of rheumatological conditions, such as rheumatoid arthritis in particular, has driven the biopharmaceutical industry to optimize all aspects of therapeutic antibody discovery and development, in order to provide further benefits for patients over and above marketed treatments, via increased clinical efficacy and patient convenience. Recent advances in many of the key aspects of antibody design that are driving this evolution, such as affinity optimization, effector function modulation, pharmacokinetic engineering, as well as developments in subcutaneous drug delivery, are reviewed here.
Export Options
About this article
Cite this article as:
C. Lowe David and J. Vaughan Tristan, Rheumatology: A Force for Change in Monoclonal Antibodies, Current Pharmaceutical Design 2015; 21 (17) . https://dx.doi.org/10.2174/1381612821666150310142202
DOI https://dx.doi.org/10.2174/1381612821666150310142202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Editorial [Hot-Topic: Molecular Mechanisms in Rheumatic Diseases:Rationale for Novel Drug Development (Guest Editor: Charles J. Malemud)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry IRAK-4 Inhibitors for Inflammation
Current Topics in Medicinal Chemistry Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Editorial [ Hot Topic: Current Drug Targets in Degenerative Joint Disease (Guest Editors: T. Aigner and E. Bartnik) ]
Current Drug Targets Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Autoimmune Hepatitis: Pathophysiology, Diagnosis and Pharmacological Therapy
Current Immunology Reviews (Discontinued) In Silico and 3D QSAR Studies of Natural Based Derivatives as Xanthine Oxidase Inhibitors
Current Topics in Medicinal Chemistry Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy The PYRIN Domain in Signal Transduction
Current Protein & Peptide Science Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?
Current Pharmaceutical Design Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery HIV-1 Rev Multimerization: Mechanism and Insights
Current HIV Research Predictive Factors for Disability as Evaluated by the Health Assessment Questionnaire in Rheumatoid Arthritis: A Literature Review
Inflammation & Allergy - Drug Targets (Discontinued)